On Wednesday, Intra-Cellular Therapies stock cleared a key performance benchmark, with its Relative Strength (RS) Rating entering into the 90-plus percentile with an improvement to 97, an increase from 89 the day before.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. This proprietary rating identifies technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the trailing 52 weeks matches up against the rest of the market.
History reveals that the stocks that go on to make the biggest gains often have an RS Rating north of 80 at the beginning of a new price run.
Looking For Winning Stocks? Try This Simple Routine
Is Intra-Cellular Therapies Stock A Buy?
Intra-Cellular Therapies stock rebounded off its 200-day moving average the last few trading days and is not currently showing a potential buy point. See if the biotech stock goes on to build a chart pattern that could launch a new move.
EPS growth dropped last quarter from 0% to -20%, but revenue rose from 106% to 120%.
Intra-Cellular Therapies stock holds the No. 36 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharmaceutcls, Regeneron Pharmaceutical and Vertex Pharmaceuticals are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
